This Release Contains Inside Information. Comment by Mark Crossley, CEO of Indivior PLC The second quarter saw Indivior make good progress against our Strategic Priorities and deliver strong performance, including our fourth consecutive quarter of double-digit growth from SUBLOCADE® (buprenorphine extended-release) injection. Based on the momentum in the business, we raised our FY 2021 guidance at the end of the quarter. Looking forward, our number one priority continues to be capturing the full transformational value of SUBLOCADE, and it is gratifying to see further uptake of this key asset in targeted Organized Health Systems (OHS), including a $7 million order from a criminal justice system that we believe is pioneering treatment of incarcerated individuals suffering from opioid use disorder (OUD). Additionally, we are seeking to strengthen our leadership position in substance use disorder by securing an exclusive agreement with Aelis Farma for their
Investegate |Indivior PLC Announcements | Indivior PLC: Indivior Raises FY 2021 Guidance investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
5 - Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. Comment by Mark Crossley, CEO of Indivior PLC We have seen an encouraging start in FY 2021 with growth in net revenue, operating profit and cash from execution against our strategic priorities. Despite the ongoing impacts of COVID-19, SUBLOCADE® (buprenorphine extended-release) injection achieved solid net revenue growth both on a sequential and year-over-year basis, and we expanded our Organized Health Systems (OHS) platform to build the foundation for future growth. Looking ahead, we are seeing healthcare restrictions in the US begin to ease from the rapid pace of COVID-19 vaccinations, which supports our expectation of increased in-person interactions with healthcare practitioners in the second half of the year. As such, we are reiterating our FY 2021 base case guidance.
Share this article
Share this article
RICHMOND, Va., April 22, 2021 /PRNewswire/ Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management and medication for opioid use disorder (MOUD) access in the U.S. which found that 85% of participants agreed that patients with OUD experienced more barriers to care during the COVID-19 pandemic.
1 Results from the study, entitled Impact of COVID-19 on OUD Management and MOUD Access in the US, were presented at the American Society of Addiction Medicine (ASAM) 2021 virtual meeting. The study was conducted to understand the impact of the COVID-19 pandemic on the management of OUD in the US from both provider and payer perspectives, as well as to gain insight into strategies adopted by healthcare organizations to overcome access barriers to OUD care and MOUD.